Overall Survival by IDO1 and PD-L1 Expression in NSCLC Patients Receiving an Immune Checkpoint Inhibitor (ICI)

被引：0
|
作者：
Moore, M. [1 ]
Hall, R. [2 ]
Mcloughlin, E. [2 ]
Melson, J. [1 ]
Horton, B. [3 ]
Mills, A. [4 ]
Gentzler, R. [2 ]
机构：
[1] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA
[2] Univ Virginia, Div Hematol Oncol, Charlottesville, VA USA
[3] Univ Virginia, Sch Med, Dept Publ Hlth Sci, Div Translat Res & Appl Stat, Charlottesville, AL USA
[4] Univ Virginia, Pathol, Charlottesville, VA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
IDO1; NSCLC; PD-L1;
D O I：
10.1016/j.jtho.2019.08.1580
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.04-75
引用
收藏
页码：S738 / S738
页数：1
相关论文
共 50 条
  • [41] Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
    Himuro, Hidetomo
    Nakahara, Yoshiro
    Igarashi, Yuka
    Kouro, Taku
    Higashijima, Naoko
    Matsuo, Norikazu
    Murakami, Shuji
    Wei, Feifei
    Horaguchi, Shun
    Tsuji, Kayoko
    Mano, Yasunobu
    Saito, Haruhiro
    Azuma, Koichi
    Sasada, Tetsuro
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (08) : 2829 - 2840
  • [42] Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
    Hidetomo Himuro
    Yoshiro Nakahara
    Yuka Igarashi
    Taku Kouro
    Naoko Higashijima
    Norikazu Matsuo
    Shuji Murakami
    Feifei Wei
    Shun Horaguchi
    Kayoko Tsuji
    Yasunobu Mano
    Haruhiro Saito
    Koichi Azuma
    Tetsuro Sasada
    Cancer Immunology, Immunotherapy, 2023, 72 : 2829 - 2840
  • [43] Clinical Significance of Soluble PD-1 and PD-L1 in Plasma of NSCLC Patients Treated with Immune Checkpoint Inhibitors
    Nakahara, Y.
    Himuro, H.
    Igarashi, Y.
    Kouro, T.
    Higashijima, N.
    Matsuo, N.
    Murakami, S.
    Wei, F.
    Horaguchi, S.
    Tsuji, K.
    Mano, Y.
    Saito, H.
    Azuma, K.
    Naoki, K.
    Sasada, T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S614 - S614
  • [44] Clinicopathologic characterization of ocular adnexal marginal zone lymphoma with a focus on PD1, PD-L1, and IDO1 expression
    Guney, Ekin
    Pekmezci, Melike
    Bloomer, Michele
    Zoltan, Laszik
    Ohgami, Robert
    Wen, Kwun Wah
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2020, 79 (06): : 681 - 681
  • [45] Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells
    Chen, Yu-Chi
    He, Xin-Ling
    Qi, Lu
    Shi, Wei
    Yuan, Luo-Wei
    Huang, Mu-Yang
    Xu, Yu-Lian
    Chen, Xiuping
    Gu, Lei
    Zhang, Le-Le
    Lu, Jin-Jian
    BIOCHEMICAL PHARMACOLOGY, 2022, 197
  • [46] COMPUTATIONAL ANALYSIS OF MUTUAL FEEDBACK REGULATIONS BETWEEN IDO1 AND PD-L1
    Zhu, Jian
    Zhu, Rebecca
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A401 - A401
  • [47] Real-World Prognostic Model of Overall Survival in Patients With Advanced NSCLC Receiving Anti-PD1/PD-L1 as 2L Monotherapy
    Julian, C.
    Machado, R.
    Girish, S.
    Chanu, P.
    Heinzmann, D.
    Harbron, C.
    Gershon, A.
    Pfeiffer, S.
    Zou, W.
    Quarmby, V.
    Zhang, Q.
    Chen, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S644 - S644
  • [48] Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy
    Suresh, Karthik
    Psoter, Kevin J.
    Voong, Khinh Ranh
    Shankar, Bairavi
    Forde, Patrick M.
    Ettinger, David S.
    Marrone, Kristen A.
    Kelly, Ronan J.
    Hann, Christine L.
    Levy, Benjamin
    Feliciano, Josephine L.
    Brahmer, Julie R.
    Feller-Kopman, David
    Lerner, Andrew D.
    Lee, Hans
    Yarmus, Lonny
    Hales, Russell K.
    D'Alessio, Franco
    Danoff, Sonye K.
    Naidoo, Jarushka
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (03) : 494 - 502
  • [49] The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
    Wang, Qingshui
    Lin, Wei
    Tang, Xiaoqiong
    Li, Suhuan
    Guo, Libin
    Lin, Yao
    Kwok, Hang Fai
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (12)
  • [50] Co-Expression of IDO1 and PD-L1 Indicates More Aggressive Features of Lung Adenocarcinoma
    Kozuma, Y.
    Takada, K.
    Toyokawa, G.
    Kohashi, K.
    Shimokawa, M.
    Kinoshita, F.
    Matsubara, T.
    Haratake, N.
    Takamori, S.
    Akamine, T.
    Hirai, F.
    Tagawa, T.
    Oda, Y.
    Maehara, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1781 - S1781
12345